Glenmark gets India approval for favipiravir as COVID-19 treatment

Glenmark Pharmaceuticals Ltd said on Friday it had received an approval from India's drugs regulator to make and sell oral antiviral drug favipiravir for treating mild-to-moderate COVID-19 patients in the country.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.